121 related articles for article (PubMed ID: 6667926)
1. Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.
Henschen A; Kehl M; Deutsch E
Hoppe Seylers Z Physiol Chem; 1983 Dec; 364(12):1747-51. PubMed ID: 6667926
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
Ebert RF; Schreiler WE; Bell WR
Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
[TBL] [Abstract][Full Text] [Related]
5. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
7. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
Soya K; Terasawa F; Okumura N
Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aalpha Arg-16----His substitution.
Southan C; Lane DA; Bode W; Henschen A
Eur J Biochem; 1985 Mar; 147(3):593-600. PubMed ID: 3979390
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
12. Genetically abnormal fibrinogens--strategies for structure elucidation, including fibrinopeptide analysis.
Henschen A; Kehl M; Southan C
Curr Probl Clin Biochem; 1984; 14():273-320. PubMed ID: 6391842
[No Abstract] [Full Text] [Related]
13. [Fibrinogen Bern II: hereditary fibrinogen variant with amino acid substitution of arginine replaced by histidine in position 16 of the A alpha chain].
Rupp C; Sievi R; Furlan M; Beck EA
Schweiz Med Wochenschr; 1983 Oct; 113(40):1460-2. PubMed ID: 6648427
[TBL] [Abstract][Full Text] [Related]
14. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).
Meyer M; Kutscher G; Stürzebecher J; Riesener G; Lutze G
Thromb Res; 2003 Jan; 109(2-3):145-51. PubMed ID: 12706644
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
Vila V; Regañón E; Aznar J; Navarro G; Salas M
Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
[TBL] [Abstract][Full Text] [Related]
19. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
Furlan M; Leupin L; Biasiutti FD; Lämmle B
Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen Geneva, a new case of A alpha 16 Arg----Cys dysfibrinogenaemia.
Furlan M; Bögli C; Hofer A; Bouvier CA; de Moerloose P
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):139-43. PubMed ID: 2130925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
